论文部分内容阅读
Bepridil,一种对心绞痛病人有肯定疗效的药物,对心脏的快内向及慢内向离子流均有抑制作用。Bepridil 的抗心律失常效用已在实验模型中得到证明。近年来的临床资料也证实 bepridil 对室上性及室性心律失常有治疗作用。现将目前对 bepridil 的临床电生理和抗心律失常特性的认识综述如下。电生理作用Duchene-Marullaz 等观察了7名健康志愿者口服 bepridil 200～600mg/day 对心电图的影响。在各剂量水平,服药者自律周期均延长,600mg/day 剂量时,自律周期从866±30ms 延长至995±45ms(p<0.001)。在这一剂量范围内,bepridil 对 PR 间期和QRS 时限无明显影响。校正 QT 间期在剂量为200mg/day 时有轻微延长,但剂量为
Bepridil, a drug that has a positive effect on angina patients, inhibits the fast inward and slow inward ion currents of the heart. The anti-arrhythmic effect of Bepridil has been demonstrated in experimental models. In recent years, clinical data also confirmed bepridil on supraventricular and ventricular arrhythmias have a therapeutic effect. The current understanding of the clinical electrophysiological and anti-arrhythmic properties of bepridil is summarized below. Electrophysiological effects Duchene-Marullaz et al observed the effect of oral bepridil 200 ~ 600mg / day on electrocardiogram in seven healthy volunteers. At each dose level, the duration of self-regulation was prolonged at 600 mg / day and the self-discipline cycle was extended from 866 ± 30 ms to 995 ± 45 ms (p <0.001). Within this dose range, bepridil had no significant effect on PR interval and QRS duration. The corrected QT interval was slightly extended at a dose of 200 mg / day but at a dose of